255 results on '"Kuo, Hsing‐Tao"'
Search Results
2. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
3. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
4. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
5. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
6. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
7. THU-365 Real-world effectiveness and safety of 8-week glecaprevir/ pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry
8. The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan
9. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
10. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
11. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
12. Iatrogenic Kaposi sarcoma of the small bowel in Crohn’s disease following short-term use of immunomodulators: a case report and review of the literature
13. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.
14. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
15. Cholestatic Hepatitis with Concomitant Nephrotic Syndrome due to Secondary Syphilis in a Young Man
16. Clinical characteristics, imaging features, and outcomes of primary hepatic angiosarcoma: A single‐center study and literature review
17. The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatients
18. Artificial intelligence predicts direct-acting antivirals failure among HCV patients: A Nationwide HCV Registry Program
19. Manipulating Diastereomeric Bicyclononynes to Sensitively Determine Enzyme Activity and Facilitate Macromolecule Conjugations
20. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
21. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
22. Clinical significance of abdominal computed tomography and colonoscopy in the evaluation of phlebosclerotic colitis.
23. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
24. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
25. Lymphocyte-Rich Hepatocellular Carcinoma with Multiple Lymphadenopathy and Positive Epstein–Barr Virus Encoding Region
26. The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry
27. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan
28. Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switchingto tenofovir alafenamide in chronic hepatitis B patients
29. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
30. Dietary choline and folate relationships with serum hepatic inflammatory injury markers in Taiwanese adults
31. A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C
32. THU-174 - The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry
33. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study
34. Comparison of the risk of gastrointestinal perforation between patients with and without rheumatoid arthritis: A nationwide cohort study in Asia
35. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV registry
36. Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide-an interim analysis
37. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
38. Mixed neuroendocrine‐non‐neuroendocrine neoplasms of the ampulla of Vater: A case report and literature review
39. Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
40. Mixed neuroendocrine‐non‐neuroendocrine neoplasms ( MiNENs ) of the ampulla of Vater: a case report and literature review
41. HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses
42. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan
43. Benefits of Stronger Neo‐Minophagen C in acute hepatitis after transarterial chemoembolization therapy for hepatomas
44. Glecaprevir/ Pibrentasvir in the Treatment of Chronic Hepatitis C Patients – A Real-World Nationwide HCV Registry Program (TACR) in Taiwan
45. Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution
46. Benefits of stronger Neo‐MinophagenC in acute hepatitis after transarterial chemoembolization therapy for hepatomas
47. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis‐related complications (Taiwanese chronic hepatitis C cohort)
48. Interrelationships among genetic C677T polymorphism of 5,10-methylenetetrahydrofolate reductase, biochemical folate status, and lymphocytic p53 oxidative damage in association with tumor malignancy and survivals of patients with hepatocellular carcinoma
49. Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
50. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.